Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated other comprehensive loss
Accumulated deficit
Total
Balance at the beginning of the period, shares at Dec. 31, 2019 631,003,568        
Balance at the beginning of the period at Dec. 31, 2019 $ 943 $ 585,623 $ (7,264) $ (455,664) $ 123,638
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 6 888     894
Issuance of shares upon exercise of stock options (in shares) 4,610,772        
Issuance of shares upon completion of public offering, net of issuance costs $ 190 90,360     90,550
Issuance of shares upon completion of public offering, net of issuance costs (in shares) 144,900,000        
Other comprehensive loss     (2,326)   (2,326)
Share-based compensation expense   1,448     1,448
Net loss       (28,167) (28,167)
Balance at the end of the period at Mar. 31, 2020 $ 1,139 678,319 (9,590) (483,831) $ 186,037
Balance at the end of the period, shares at Mar. 31, 2020 780,514,340        
Balance at the beginning of the period, shares at Dec. 31, 2020 928,754,958       928,754,958
Balance at the beginning of the period at Dec. 31, 2020 $ 1,325 935,706 (10,048) (585,756) $ 341,227
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 6 529     535
Issuance of shares upon exercise of stock options (in shares) 4,062,210        
Other comprehensive loss     (176)   (176)
Share-based compensation expense   5,334     5,334
Net loss       (37,763) (37,763)
Balance at the end of the period at Mar. 31, 2021 $ 1,331 $ 941,569 $ (10,224) $ (623,519) $ 309,157
Balance at the end of the period, shares at Mar. 31, 2021 932,817,168       932,817,168